East Meets West - the Quest for Cure

Who We Are

HighTide Therapeutics Inc. is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional therapies for metabolic and digestive diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for type 2 diabetes (T2DM), nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). HTD1801, the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801, has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

Our Mission

Mission:Focus on patient‑centric drug development to bring total and optimal benefits to patients

Vision:  Become a leading and respected globally integrated biotech company


· Simplicity is the ultimate sophistication 

· Mind and hand

· All for one and one for all, united we stand 

· Resilient growth 

· Think win/win

Leadership Team


We will contact you as soon as possible

© 2020 HighTide Therapeutics Inc.

Legal StatementPrivacy PolicyCookie Policy


Follow Us

© 2020 HighTide Therapeutics Inc.